0
Back To Top Jump Location
Sign In  | Cart
Left Shadow
Right Shadow
Clinical Research |

Prognostic Value of High-Dose Dobutamine Stress Magnetic Resonance Imaging in 1,493 Consecutive Patients: Assessment of Myocardial Wall Motion and Perfusion FREE

Grigorios Korosoglou, MD; Yacine Elhmidi, MD; Henning Steen, MD; Dieter Schellberg, PhD; Nina Riedle, MD; Johannes Ahrens, MS; Stephanie Lehrke, MD; Constanze Merten, MD; Dirk Lossnitzer, MD; Jannis Radeleff, MD; Christian Zugck, MD; Evangelos Giannitsis, MD; Hugo A. Katus, MD
[+] Author Information

The authors have reported that they have no relationships to disclose.Reprint requests and correspondence: Dr. Grigorios Korosoglou, University of Heidelberg, Department of Cardiology, Im Neuenheimer Feld 410, Heidelberg 69120, Germany

American College of Cardiology Foundation

J Am Coll Cardiol. 2010;56(15):1225-1234. doi:10.1016/j.jacc.2010.06.020
Published online

Objectives  This study sought to determine the prognostic value of wall motion and perfusion assessment during high-dose dobutamine stress (DS) cardiac magnetic resonance imaging (MRI) in a large patient cohort.

Background  DS-MRI offers the possibility to integrate myocardial perfusion and wall motion analysis in a single examination for the detection of coronary artery disease (CAD).

Methods  A total of 1,493 consecutive patients with suspected or known CAD underwent DS-MRI, using a standard protocol in a 1.5-T magnetic resonance scanner. Wall motion and perfusion were assessed at baseline and during stress, and outcome data including cardiac death, nonfatal myocardial infarction (“hard events”), and “late” revascularization performed >90 days after the MR scans were collected during a 2 ± 1 year follow-up period.

Results  Fifty-three hard events, including 14 cardiac deaths and 39 nonfatal infarctions, occurred during the follow-up period, whereas 85 patients underwent “late” revascularization. Using multivariable regression analysis, an abnormal result for wall motion or perfusion during stress yielded the strongest independent prognostic value for both hard events and late revascularization, clearly surpassing that of clinical and baseline magnetic resonance parameters (for wall motion: adjusted hazard ratio [HR] of 5.9 [95% confidence interval (CI): 2.5 to 13.6] for hard events and of 3.1 [95% CI: 1.7 to 5.6] for late revascularization, and for perfusion: adjusted HR of 5.4 [95% CI: 2.3 to 12.9] for hard events and of 6.2 [95% CI: 3.3 to 11.3] for late revascularization, p < 0.001 for all).

Conclusions  DS-MRI can accurately identify patients who are at increased risk for cardiac death and myocardial infarction, separating them from those with normal findings, who have very low risk for future cardiac events. (Prognostic Value of High Dose Dobutamine Stress Magnetic Resonance Imaging; NCT00837005)

Figures in this Article
CABG

coronary artery bypass graft

CAD

coronary artery disease

DS

dobutamine stress

LV

left ventricle

LVEF

left ventricular ejection fraction

MDRD

Modified Diet in Renal Disease

MRI

magnetic resonance imaging

PCI

percutaneous coronary intervention

WMA

wall motion abnormalities

High-dose dobutamine/atropine stress (DS) cardiac magnetic resonance imaging (MRI) is incorporated into daily clinical practice for the detection of coronary artery disease (CAD). This technique offers the possibility to integrate myocardial perfusion and wall motion analysis in a single examination. In this regard, recent data suggest that the assessment of myocardial wall motion and perfusion during a single dobutamine stress session may enhance the sensitivity of the technique for ischemia detection (1).

However, to date, limited data are available on the prognostic value of high-dose DS-MRI in large patient cohorts receiving optimal medical therapy (2). Assessment of long-term outcome of DS-MRI is important because this test may identify both high-risk patients who would benefit from invasive diagnostic and therapy, and lower-risk patients in whom additional procedures and intensive medical follow-up are not required.

In the present study, we sought to determine the association between DS-MRI findings with future cardiac events in a large patient cohort (n = 1,493). Furthermore, the potential complementary value of perfusion and wall motion analysis was investigated, and analysis of subgroups was conducted to evaluate the usefulness of DS-MRI in patients with low, intermediate, and high pre-test probability for CAD.

Study population

The study was conducted in accordance with the standards of our local ethics committee. From December 2004 through January 2008, consecutive patients (n = 1,787) were referred to our institution for clinically indicated DS-MRI due to suspected or known CAD. Written informed consent was obtained from all patients before the magnetic resonance examination. Patients with nonsinus rhythm, unstable angina, severe arterial hypertension (>200/120 mm Hg), moderate or severe valvular disease, and general contraindications to MRI (implanted pacemakers or defibrillators) were excluded.

A total of 1,784 patients were screened, and diagnostic stress examinations (positive for ischemia or negative but with achievement of ≥85% of the age-predicted heart rate) were obtained in 1,510 patients. Reasons for discontinuation of the stress procedures included claustrophobia, large body habitus, arrhythmias, failure to achieve the target heart rate, and side effects. Furthermore, during the follow-up period, 17 of 1,510 patients (1.1%) were lost, so that 1,493 patients had complete stress MRI and follow-up information, and constituted our patient population (Figure 1).

Grahic Jump Location
Figure 1

Flow Chart of 1,493 Consecutive Patients Who Completed High-Dose DS-MRI and Clinical Follow-Up

A total of 1,784 consecutive patients were screened for clinically indicated dobutamine stress magnetic resonance imaging (DS-MRI), and diagnostic stress examinations (positive for ischemia or negative but with achievement of ≥85% of the age-predicted heart rate [HR]) were obtained in 1,510 patients. During the follow-up period, 17 patients were lost, so that 1,493 patients had complete stress MRI and follow-up data, and constituted our patient population.

Traditional risk factors for CAD, including advanced age (≥45 years for men, ≥55 years for women), arterial hypertension, hyperlipidemia, current or prior smoking, diabetes mellitus, history of CAD, and a family history of CAD were recorded at the time of imaging. Furthermore, the total number of cardiovascular risk factors (range 0 to 7) and the Duke Clinical Score, which incorporates clinical presentation of chest pain, age, sex, and atherogenic risk factors (3) were calculated. Hereby, patients were categorized into a low (<30%), intermediate (30% to 70%), or high (>70%) pre-test probability group for CAD, as reported previously (4). Subsequently, patients were separated into 2 major groups for further analysis, including those with low or intermediate risk for CAD and those with high pre-test probability or known CAD. In addition, renal function, which is a major determinant of cardiac-related outcomes in patients with CAD (5), was calculated using the Modified Diet in Renal Disease (MDRD) equation (6).

Cardiovascular MR examination

Patients were examined in a clinical 1.5-T whole-body MR scanner Achieva system (Philips Medical Systems, Best, the Netherlands) using a 5-element cardiac phased-array receiver coil. The 4-, 2-, and 3-chamber and 3 short-axis views (apical, mid-ventricular, and basal) were used for wall motion assessment at baseline and were repeated during each stage of inotropic stimulation. Three identical short-axis views were used for assessment of myocardial perfusion at baseline and at peak stress. Dobutamine was infused intravenously during 3-min stages, at incremental doses of 10, 20, 30, and 40 μg/kg of body weight per minute until at least 85% of the age-predicted heart rate was reached (6). If, at the peak dose of dobutamine infusion, the target heart rate was not achieved, atropine was administrated in 0.25-mg increments up to a maximal dose of 2.0 mg. Stress testing was discontinued when the target heart rate was achieved, or when 1 of the following occurred: new or worsening wall motion abnormalities (WMA), severe chest pain or dyspnea, decrease in systolic blood pressure of ≥40 mm Hg, severe arterial hypertension (≥240/130 mm Hg), or severe arrhythmias.

Cine and Perfusion Imaging

A steady-state free precession sequence was used to obtain the cine images of the 4-, 2-, and 3-chamber views and the 3 short-axis planes (apical, mid-ventricular, and basal) with an 8-mm slice thickness. For perfusion imaging, a single-shot, segmented k-space, turbo gradient echo/echo planar imaging sequence was used with a 10-mm slice thickness. Images were acquired during the first pass of 0.05 mmol/kg of body weight gadolinium-DTPA (Magnevist, Bayer, Germany).

Interpretation of Myocardial Wall Motion and Perfusion

For interpretation of wall motion, corresponding rest and peak stress cine images were displayed using View Forum software (Philips Medical Systems). Seventeen myocardial segments were evaluated according to American Heart Association guidelines (7), and wall motion was graded semiquantitatively using a 3-point scale (0 = normal wall motion, 1 = hypokinesia, 2 = akinesia or dyskinesia) (810). Inducible ischemia was considered present in cases of new or worsening WMA of ≥1 grade during stress. Both short- and long-axis views were considered, and WMA in 1 view was regarded sufficient for the detection of inducible ischemia. For the evaluation of myocardial perfusion, the transmural extent of a perfusion deficit was determined from the single dynamic image showing the maximum extent of regional hypoenhancement. The transmural extent of perfusion deficits was evaluated visually (0 = no defect; 1 = 1% to 25%; 2 = 26% to 50%; 3 = 51% to 75%; and 4 = 76% to 100%) both at baseline and during stress. A regional worsening of the transmural score during stress by ≥1 in any segment, which persisted for >5 consecutive image frames beyond peak myocardial enhancement of the remote myocardium, which appeared most normal, was considered indicative of myocardial ischemia. When uncertainty existed, signal intensity curves from a remote myocardial region were derived over time to determine the time frame of peak myocardial enhancement. Perfusion defects that were seen at baseline and did not increase during stress (i.e., fixed defects associated with prior infarction) were not considered. In 6, 3 examples are provided of studies with: 1) normal findings; 2) a subendocardial inducible perfusion abnormality but without inducible WMA; and 3) inducible WMA and perfusion defects.

Follow-up data and definition of study end points

Personnel unaware of the stress results contacted each subject or an immediate family member, and the date of this contact was used for calculating the follow-up time duration. Outcome data were collected from a standardized questionnaire and determined from patient interviews at the outpatient clinic or by telephone interviews. Reported clinical events were confirmed by review of the corresponding medical records in our electronic Hospital Information System, contact with the general practitioner, referring cardiologist, or the treating hospital. Cardiac death and nonfatal myocardial infarction were registered as “hard events.” Other events included clinically indicated revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG). Because the results of the MR examination may have triggered revascularization procedures (thereby altering the subsequent event rate), “early” revascularization procedures within 90 days of MRI were not considered (n = 158 patients), and patients were censored at the time of revascularization.

Statistical analysis

Continuous variables are expressed as mean ± SD, whereas categorical variables are expressed as proportions. Unpaired Student t tests or repeated-measures ANOVA with Bonferroni correction for multiple comparisons were used to compare continuous variables. Group differences between ordinal variables were tested using the exact Mann-Whitney test, and differences between nominal variables were assessed using Fisher exact tests. All tests were 2-tailed. In a random sample of 40 studies, wall motion and perfusion data were independently evaluated by 2 observers (H.S. and G.K.), and agreement was calculated using κ statistics. Kaplan-Meier curves were used to estimate the distribution of cardiac events as a function of the follow-up duration, and the association of baseline and MR findings with outcomes was investigated using Cox proportional hazards models and univariate and multivariable procedures. For multivariable analysis, combined assessment studies were considered abnormal, according to pre-specified criteria, if either WMA or perfusion defects were present; and normal if both modalities yielded normal findings. In order to investigate the complementary value of wall motion and perfusion analysis, the value of WMA for the assessment of hard events was tested in the presence and absence of perfusion deficits. Furthermore, subgroup analysis was conducted in this context in patients with known CAD, resting WMA, and left ventricular hypertrophy. A p value of <0.05 was considered statistically significant.

Outcomes

Data were prospectively collected at least 6 months after the MR examination (2.0 ± 1.0 years, range 0.5 to 4.0 years). Fifty-three hard events, including 14 cardiac deaths and 39 nonfatal myocardial infarctions, occurred during the follow-up period. In 158 patients, early revascularization was performed within 90 days after the MR examination (137 by PCI and 21 by CABG), and 85 patients underwent late revascularization (68 by PCI and 17 by CABG).

The baseline characteristics and hemodynamic data of patients with (n = 53) and without hard events (n = 1,440) are illustrated in (Table 1). Furthermore, data including reasons for referral and medications are presented according to pre-test probabilities in (6).

Table Grahic Jump Location
Table 1Demographic and Baseline MR Data of Patients With and Without Hard Events
Safety Issues

No myocardial infarctions or fatal complications occurred during imaging. Severe side effects requiring the termination of the study occurred in 15 (1.0%) patients due to sustained ventricular tachycardia (n = 3), ventricular fibrillation (n = 2), severe hypotension (n = 4), and severe hypertension (n = 6). The majority of the patients with life-threatening arrhythmias and severe hypotension (7 out of 9) had severely impaired resting LV function.

Univariate and Multivariable Analyses

By univariate analysis, significant associations were observed between several clinical parameters, including renal function and stress MRI findings for hard events and late revascularization (Figure 2).

Grahic Jump Location
Figure 2

Univariate Value of Clinical Parameters, Renal Function, Baseline MRI, and DS-MRI for the Assessment of Hard Events and Late Revascularization

Significant associations were observed between several clinical parameters, including renal function and stress magnetic resonance imaging (MRI) findings for hard events. Similar associations were observed between clinical parameters such as hypertension, hyperlipidemia, and type 2 diabetes mellitus with late revascularization. *p < 0.05; †p < 0.01; §p < 0.001. CAD = coronary artery disease; DS-MRI = dobutamine stress magnetic resonance imaging.

Using multivariable analysis, renal function and baseline ejection fraction were independently associated with hard events, whereas the total number of risk factors was associated with late revascularization procedures. In both models, an abnormal result for myocardial wall motion or perfusion was most strongly associated with outcome (Figure 3).

Grahic Jump Location
Figure 3

Multivariable Value of Clinical Parameters, Renal Function, Baseline MRI, and DS-MRI for the Assessment of Hard Events and Late Revascularization

Renal function and baseline ejection fraction were independently associated with hard events. The total number of risk factors, conversely, was associated with late revascularization procedures. In both models, an abnormal result for myocardial wall motion or perfusion was most strongly associated with outcome. *p < 0.05; §p < 0.001. WMA = wall motion abnormalities; other abbreviations as in (Figure 2).

Survival Analysis
Complementary value of wall motion and perfusion analysis

Kaplan-Meier curves based on stress MR findings can be appreciated in (Figure 4). The presence of inducible WMA and perfusion deficits was associated with a markedly higher rate of hard events ((Figure 4)A and Figure 4B) and revascularization procedures ((Figure 4)C and Figure 4D). Conversely, patients with normal DS-MRI (n = 1,193) yielded a very low event rate for hard events (1 cardiac death; 4 myocardial infarctions) and for revascularization procedures over the following 4 years (4 by CABG and 11 by PCI).

Grahic Jump Location
Figure 4

Value of Wall Motion and Perfusion Results

Kaplan-Meier curves for hard events and revascularization-free survival based on wall motion (A and B) and perfusion test results (C and D). The detection of inducible wall motion abnormalities (WMA) resulted in poorer outcome in patients with and without diagnosed inducible perfusion deficits (blue arrows in E and F), whereas the detection of inducible perfusion deficits added value to the risk stratification only in the absence of inducible WMA (red arrow in G).

The presence of inducible WMA added value to risk stratification of patients with and without diagnosed inducible perfusion deficits, contributing to significantly poorer outcome in both cases (blue arrows in (Figure 4)E and Figure 4F). Conversely, perfusion deficits added value to the risk stratification only in the absence of inducible WMA (red arrow in Figure 4G). In patients with diagnosed inducible WMA on the other hand, the presence of additional perfusion deficits contributed to significantly poorer outcome only in patient subgroups with resting WMA, whereas a trend was noted in this context for subgroups with known CAD and LV hypertrophy (red arrows in Figure 5).

Grahic Jump Location
Figure 5

Complementary Value of Myocardial Perfusion for the Assessment of Hard Events in Patients With Diagnosed Inducible WMA

In patients with diagnosed inducible wall motion abnormalities (WMA), the presence of additional perfusion deficits contributed to significantly poorer outcome only in subgroups with resting WMA, whereas a trend was noted in this context for patients with known coronary artery disease (CAD) and left ventricular (LV) hypertrophy (red arrows in B, D, and F versus A, C, and E).

Division into subgroups
Pre-Test Probability for CAD

Both in patients with low or intermediate risk and in those with high risk, the presence of inducible WMA was associated with hard events ((Figure 6)A and Figure 6B). Furthermore, the presence of inducible WMA was associated with an equally adverse outcome in both groups (Figure 6C). Conversely, the absence of WMA was associated with excellent hard events–free survival (>99.5%) only in the patients with low or intermediate risk, whereas patients without WMA but high risk still showed a significant number of subsequent hard events during follow-up (∼5%) (Figure 6D).

Grahic Jump Location
Figure 6

Survival Analysis in Patient Subgroups

Kaplan-Meier curves for hard events in patients with low or intermediate versus high risk (A and B); in patients with versus without inducible WMA sorted by pre-test probability (C and D); and in patients with severely versus nonseverely impaired LV function (E and F). Abbreviations as in (Figure 5).

Baseline Ejection Fraction

Excluding patients with baseline ejection fraction <35% (n = 58), an excellent outcome was observed in 1,149 patients with normal DS-MRI (no cardiac deaths and only 1 nonfatal infarction) (Figure 6E). Conversely, patients with ejection fraction <35% had an increased rate of hard events irrespective of stress MR findings (Figure 6F).

Influence of Diuretic Therapy and Hemodynamic Response

In patients who received treatment with diuretics, WMA showed a trend for less robust assessment of future events compared with those who did not receive diuretics (p = 0.06 for interaction), whereas no interaction was observed for perfusion analysis in this context. On the other hand, assessment of subsequent hard events was similar in patients with blood pressure increase during DS-MRI compared with those with decrease of systemic blood pressure due to systemic vasodilatation.

Observer Variability

Agreement between observers interpreting wall motion and myocardial perfusion was 90% (κ = 0.73) and 93% (κ = 0.76), respectively for test positivity versus test negativity on a patient level.

The MR findings presented in our study, in what we believe to be the largest cohort so far, of 1,493 patients who underwent high-dose DS-MRI indicate that: 1) inducible ischemia diagnosed by DS-MRI identifies patients at increased risk for hard events and for late revascularization procedures independent of conventional atherogenic risk factors and of baseline MR findings; 2) myocardial wall motion and perfusion assessment yielded complementary diagnostic characteristics. The presence of inducible WMA was of incremental value for the risk stratification of patients with and without inducible perfusion deficits, whereas perfusion deficits contributed to poorer outcome only in the absence of diagnosed inducible WMA; and 3) a normal stress MRI is prognostically most valuable in patients with low or intermediate risk, because patients at high risk still exhibit a non-negligible rate of subsequent hard events even in the absence of inducible ischemia.

Previous studies

Several findings of our study are consistent with those reported in previous stress studies. Thus, using a combined protocol with 2 stressors (adenosine and dobutamine) Jahnke et al. (11) previously reported on the incremental prognostic value of stress MRI over clinical parameters. In another interesting study, dipyridamole stress MRI also yielded independent information for the assessment of cardiac outcome (12). Furthermore, our patients with inducible WMA exhibited a cardiac event rate (∼7% to 9% annual rate for cardiac death/nonfatal infarction), which is very similar to those previously reported by stress echocardiography and nuclear scintigraphy (1314).

Methodological aspects and complementary value of perfusion and wall motion

Previous MR studies used 2 stressors in the same patient, making the test less feasible and more time-consuming than stress echocardiography. In our study, a single stressor (dobutamine) was used both for the evaluation of wall motion and perfusion. This protocol may be more useful in the clinical routine, particularly with high-volume MR laboratories, due to reduced complexity and lower time spent (∼25 to 30 min for single stress vs. ∼45 min for dual stress).

Based on the ischemic cascade, perfusion assessment is expected to perform better in ischemia detection, preceding the development of WMA (1). However, in agreement with previous studies, the assessment of wall motion during stress was the most powerful index, yielding the highest hazard ratio for subsequent hard events. Furthermore, the presence of inducible WMA added value to risk stratification of patients with and without inducible perfusion deficits. Conversely, the consideration of myocardial perfusion test results was useful mainly in the absence of inducible WMA. Implementing our results in the clinical work flow, the following algorithm is proposed: if an inducible WMA is not seen during a diagnostic DS-MRI procedure, the administration of contrast for the evaluation of myocardial perfusion is recommended. If an inducible WMA is already detected by cine imaging on the other hand, the value of additional perfusion assessment may be limited to patients with resting WMA and possibly to those with known CAD and LV hypertrophy, where the detection of true positive inducible WMA may be more challenging (1516).

Certainly, technical limitations with myocardial perfusion MR imaging, such as motion artifacts and lower resolution with increasing heart rates during stress testing, should be considered when interpreting our results. Furthermore, with our current perfusion protocol, less myocardium is visualized, so that ischemia in regions like the apical cap (segment 17) or the true basal inferior wall may be missed. These shortcomings, however, may be circumvented in future studies by the recent availability of multichannel cardiac coils, which may allow for 3D first-pass perfusion scans.

Clinical aspects of survival analysis

By dividing our patients into those at high risk versus those at low or intermediate risk (3), we found that all groups with inducible WMA had a high post-test probability for hard events. On the other hand, in the absence of inducible WMA, only patients with low or intermediate risk showed an excellent long-term outcome (event-free survival of >99.5%), whereas patients with high risk still yielded a significant number of subsequent hard events (∼5%). Thus, the value of a negative stress MR examination may be higher in patients with low or intermediate risk than in those with high risk, which may still experience a considerable rate of cardiac events despite negative test results. However, even in patients with known CAD, stress MRI examinations may be clinically valuable in order to guide revascularization procedures in patients with ischemic myocardium (17), as recently proposed by the COURAGE (Clinical Outcomes Utilization Revascularization and Aggressive Drug Evaluation) trial substudy (2) (6).

In addition, in patients without severely impaired LV function, no cardiac deaths and only 1 nonfatal myocardial infarction were recorded in the latter, in the presence of normal DS-MRI, which represents an excellent outcome. Conversely, in patients with severely impaired LV function, DS-MRI test results did not predict outcome beyond the assessment of resting LV ejection fraction, which is in agreement with previous observations (18). Simultaneously, this patient group exhibited increased risk for life-threatening complications during imaging.

Interestingly, in patients who received diuretics, WMA showed a trend for less robust assessment of future events compared with those without treatment. Possibly, reduced LV volume in patients treated with diuretics may result in reduced wall stress, diminishing myocardial oxygen consumption associated with any given heart rate. This may prevent the development of inducible WMA, weakening the diagnostic capability of DS-MRI in this patient subgroup.

Furthermore, it must be noted that since stress test results were used to structure treatment, and a great number of patients underwent early revascularization, the discriminative power of DS-MRI may be overall underestimated in our study.

Safety and feasibility aspects

The number of side effects during imaging in our study was relatively high, especially in patients with reduced LV function. This may be attributed to the high proportion of high-risk patients that were included. However, the safety profile reported in our study is similar to that reported in other MR studies and by other methodologies using dobutamine infusions (1920). Furthermore, the real success rate of DS-MRI was relatively low (only in 1,510 of 1,784 patients initially screened). However, in the absence of general contraindications to MRI or to dobutamine, diagnostic stress examinations were obtained in 1,510 of 1,658 patients (91%). These numbers are comparable to those reported in previous MRI (19) and echocardiography (21) studies, where around 10% of patients will have nondiagnostic results because of an insufficient hemodynamic response or limiting side effects.

Study limitations

Our study population arises from a referral population at a tertiary care university hospital so that a high proportion of high-risk patients was included. This may limit the extrapolation of our findings to ambulatory settings with lower-risk cohorts. Furthermore, wall motion and perfusion of the myocardium were assessed visually, which is subjective and depends on the expertise of the observers. Given the association between myocardial strain response during stress and cardiac outcome (22), and the ability of strain-encoded MRI techniques to quantify myocardial strain during stress procedures (23), it would be useful to investigate the incremental value of strain quantification with DS-MRI in future trials. Increased LV mass and concentric remodeling of the left ventricle were shown to be important predictors of increased cardiovascular risk in previous echocardiographic studies (2425). Furthermore, late gadolinium enhancement is a clinically established technique for the detection of myocardial infarction and was recently shown to predict adverse outcome independent of segmental WMA (26) or inducible perfusion defects during stress testing (27). In our study, patterns of LV geometric remodeling and the presence of delayed enhancement were not systematically analyzed, which is a limitation. Such conditions may have influenced cardiac outcome of individuals with high pre-test probability, even in the absence of positive stress test results, and merit further investigation in future studies. Furthermore, clinicians had access to the results of stress testing, which obviously triggered early revascularization in the majority of patients with inducible ischemia.

DS-MRI is diagnostic procedure that allows for risk stratification and guides revascularization procedures in patients with ischemic heart disease. The assessment of wall motion and perfusion during stress testing can accurately identify patients with positive findings who are at increased risk for cardiac events, and separate them from those with normal findings who are at much lower risk. Furthermore, myocardial wall motion and perfusion assessment yielded complementary values for the prediction of hard cardiac events, whereas a normal stress test was prognostically most valuable in patients with low or intermediate pre-test probability and in those with nonseverely impaired baseline LV function.

The authors thank their MR technicians Angela Stöcker-Wochele, Birgit Hoerig, and Sina Fenker for the high-quality cardiac stress MR examinations.

For additional figures and table, please see the online version of this article.

Prognostic Value of High-Dose Dobutamine Stress Magnetic Resonance Imaging in 1493 Consecutive Patients. Assessment of Myocardial Wall Motion and Perfusion.

Gebker  R., Jahnke  C., Manka  R.; Additional value of myocardial perfusion imaging during dobutamine stress magnetic resonance for the assessment of coronary artery disease. Circ Cardiovasc Imaging. 1 2008:122-130.
CrossRef | PubMed
Boden  W.E., O'Rourke  R.A., Teo  K.K.; Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 356 2007:1503-1516.
CrossRef | PubMed
Pryor  D.B., Shaw  L., McCants  C.B.; Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 118 1993:81-90.
PubMed
Meijboom  W.B., van Mieghem  C.A., Mollet  N.R.; 64-slice computed tomography coronary angiography in patients with high, intermediate, or low pretest probability of significant coronary artery disease. J Am Coll Cardiol. 50 2007:1469-1475.
CrossRef | PubMed
Hakeem  A., Bhatti  S., Dillie  K.S.; Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation. 118 2008:2540-2549.
CrossRef | PubMed
Levey  A.S., Coresh  J., Greene  T.; Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 145 2006:247-254.
PubMed
Cerqueira  M.D., Weissman  N.J., Dilsizian  V.; Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 105 2002:539-542.
CrossRef | PubMed
Korosoglou  G., Dubart  A.E., DaSilva  K.G.  Jr.; Real-time myocardial perfusion imaging for pharmacologic stress testing: added value to single photon emission computed tomography. Am Heart J. 151 2006:131-138.
CrossRef | PubMed
Kaandorp  T.A., Bax  J.J., Schuijf  J.D.; Head-to-head comparison between contrast-enhanced magnetic resonance imaging and dobutamine magnetic resonance imaging in men with ischemic cardiomyopathy. Am J Cardiol. 93 2004:1461-1464.
CrossRef | PubMed
Korosoglou  G., da Silva  K.G.  Jr., Labadze  N.; Real-time myocardial contrast echocardiography for pharmacologic stress testing: is quantitative estimation of myocardial blood flow reserve necessary?. J Am Soc Echocardiogr. 17 2004:1-9.
CrossRef | PubMed
Jahnke  C., Nagel  E., Gebker  R.; Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 115 2007:1769-1776.
CrossRef | PubMed
Bodi  V., Sanchis  J., Lopez-Lereu  M.P.; Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease. J Am Coll Cardiol. 50 2007:1174-1179.
CrossRef | PubMed
Krivokapich  J., Child  J.S., Gerber  R.S., Lem  V., Moser  D.; Prognostic usefulness of positive or negative exercise stress echocardiography for predicting coronary events in ensuing twelve months. Am J Cardiol. 71 1993:646-651.
CrossRef | PubMed
Geleijnse  M.L., Elhendy  A., van Domburg  R.T.; Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. J Am Coll Cardiol. 28 1996:447-454.
CrossRef | PubMed
Smart  S.C., Knickelbine  T., Malik  F., Sagar  K.B.; Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. Circulation. 101 2000:258-263.
CrossRef | PubMed
Hoffmann  R., Lethen  H., Marwick  T.; Analysis of interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. J Am Coll Cardiol. 27 1996:330-336.
CrossRef | PubMed
Shaw  L.J., Berman  D.S., Maron  D.J.; Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 117 2008:1283-1291.
CrossRef | PubMed
Dall'Armellina  E., Morgan  T.M., Mandapaka  S.; Prediction of cardiac events in patients with reduced left ventricular ejection fraction with dobutamine cardiovascular magnetic resonance assessment of wall motion score index. J Am Coll Cardiol. 52 2008:279-286.
CrossRef | PubMed
Wahl  A., Paetsch  I., Gollesch  A.; Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J. 25 2004:1230-1236.
CrossRef | PubMed
Poldermans  D., Fioretti  P.M., Boersma  E.; Long-term prognostic value of dobutamine-atropine stress echocardiography in 1737 patients with known or suspected coronary artery disease: a single-center experience. Circulation. 99 1999:757-762.
CrossRef | PubMed
Geleijnse  M.L., Fioretti  P.M., Roelandt  J.R.; Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol. 30 1997:595-606.
CrossRef | PubMed
Bjork Ingul  C., Rozis  E., Slordahl  S.A., Marwick  T.H.; Incremental value of strain rate imaging to wall motion analysis for prediction of outcome in patients undergoing dobutamine stress echocardiography. Circulation. 115 2007:1252-1259.
PubMed
Korosoglou  G., Lehrke  S., Wochele  A.; Strain-encoded CMR for the detection of inducible ischemia during intermediate stress. J Am Coll Cardiol Img. 3 2010:361-371.
Verdecchia  P., Schillaci  G., Borgioni  C.; Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 25 1995:871-878.
CrossRef | PubMed
Devereux  R.B., Wachtell  K., Gerdts  E.; Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 292 2004:2350-2356.
CrossRef | PubMed
Kwong  R.Y., Chan  A.K., Brown  K.A.; Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 113 2006:2733-2743.
CrossRef | PubMed
Steel  K., Broderick  R., Gandla  V.; Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation. 120 2009:1390-1400.
CrossRef | PubMed

Figures

Grahic Jump Location
Figure 1

Flow Chart of 1,493 Consecutive Patients Who Completed High-Dose DS-MRI and Clinical Follow-Up

A total of 1,784 consecutive patients were screened for clinically indicated dobutamine stress magnetic resonance imaging (DS-MRI), and diagnostic stress examinations (positive for ischemia or negative but with achievement of ≥85% of the age-predicted heart rate [HR]) were obtained in 1,510 patients. During the follow-up period, 17 patients were lost, so that 1,493 patients had complete stress MRI and follow-up data, and constituted our patient population.

Grahic Jump Location
Figure 2

Univariate Value of Clinical Parameters, Renal Function, Baseline MRI, and DS-MRI for the Assessment of Hard Events and Late Revascularization

Significant associations were observed between several clinical parameters, including renal function and stress magnetic resonance imaging (MRI) findings for hard events. Similar associations were observed between clinical parameters such as hypertension, hyperlipidemia, and type 2 diabetes mellitus with late revascularization. *p < 0.05; †p < 0.01; §p < 0.001. CAD = coronary artery disease; DS-MRI = dobutamine stress magnetic resonance imaging.

Grahic Jump Location
Figure 3

Multivariable Value of Clinical Parameters, Renal Function, Baseline MRI, and DS-MRI for the Assessment of Hard Events and Late Revascularization

Renal function and baseline ejection fraction were independently associated with hard events. The total number of risk factors, conversely, was associated with late revascularization procedures. In both models, an abnormal result for myocardial wall motion or perfusion was most strongly associated with outcome. *p < 0.05; §p < 0.001. WMA = wall motion abnormalities; other abbreviations as in (Figure 2).

Grahic Jump Location
Figure 4

Value of Wall Motion and Perfusion Results

Kaplan-Meier curves for hard events and revascularization-free survival based on wall motion (A and B) and perfusion test results (C and D). The detection of inducible wall motion abnormalities (WMA) resulted in poorer outcome in patients with and without diagnosed inducible perfusion deficits (blue arrows in E and F), whereas the detection of inducible perfusion deficits added value to the risk stratification only in the absence of inducible WMA (red arrow in G).

Grahic Jump Location
Figure 5

Complementary Value of Myocardial Perfusion for the Assessment of Hard Events in Patients With Diagnosed Inducible WMA

In patients with diagnosed inducible wall motion abnormalities (WMA), the presence of additional perfusion deficits contributed to significantly poorer outcome only in subgroups with resting WMA, whereas a trend was noted in this context for patients with known coronary artery disease (CAD) and left ventricular (LV) hypertrophy (red arrows in B, D, and F versus A, C, and E).

Grahic Jump Location
Figure 6

Survival Analysis in Patient Subgroups

Kaplan-Meier curves for hard events in patients with low or intermediate versus high risk (A and B); in patients with versus without inducible WMA sorted by pre-test probability (C and D); and in patients with severely versus nonseverely impaired LV function (E and F). Abbreviations as in (Figure 5).

Tables

Table Grahic Jump Location
Table 1Demographic and Baseline MR Data of Patients With and Without Hard Events

Interactive Graphics

Video

References

Gebker  R., Jahnke  C., Manka  R.; Additional value of myocardial perfusion imaging during dobutamine stress magnetic resonance for the assessment of coronary artery disease. Circ Cardiovasc Imaging. 1 2008:122-130.
CrossRef | PubMed
Boden  W.E., O'Rourke  R.A., Teo  K.K.; Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 356 2007:1503-1516.
CrossRef | PubMed
Pryor  D.B., Shaw  L., McCants  C.B.; Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 118 1993:81-90.
PubMed
Meijboom  W.B., van Mieghem  C.A., Mollet  N.R.; 64-slice computed tomography coronary angiography in patients with high, intermediate, or low pretest probability of significant coronary artery disease. J Am Coll Cardiol. 50 2007:1469-1475.
CrossRef | PubMed
Hakeem  A., Bhatti  S., Dillie  K.S.; Predictive value of myocardial perfusion single-photon emission computed tomography and the impact of renal function on cardiac death. Circulation. 118 2008:2540-2549.
CrossRef | PubMed
Levey  A.S., Coresh  J., Greene  T.; Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 145 2006:247-254.
PubMed
Cerqueira  M.D., Weissman  N.J., Dilsizian  V.; Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 105 2002:539-542.
CrossRef | PubMed
Korosoglou  G., Dubart  A.E., DaSilva  K.G.  Jr.; Real-time myocardial perfusion imaging for pharmacologic stress testing: added value to single photon emission computed tomography. Am Heart J. 151 2006:131-138.
CrossRef | PubMed
Kaandorp  T.A., Bax  J.J., Schuijf  J.D.; Head-to-head comparison between contrast-enhanced magnetic resonance imaging and dobutamine magnetic resonance imaging in men with ischemic cardiomyopathy. Am J Cardiol. 93 2004:1461-1464.
CrossRef | PubMed
Korosoglou  G., da Silva  K.G.  Jr., Labadze  N.; Real-time myocardial contrast echocardiography for pharmacologic stress testing: is quantitative estimation of myocardial blood flow reserve necessary?. J Am Soc Echocardiogr. 17 2004:1-9.
CrossRef | PubMed
Jahnke  C., Nagel  E., Gebker  R.; Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 115 2007:1769-1776.
CrossRef | PubMed
Bodi  V., Sanchis  J., Lopez-Lereu  M.P.; Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease. J Am Coll Cardiol. 50 2007:1174-1179.
CrossRef | PubMed
Krivokapich  J., Child  J.S., Gerber  R.S., Lem  V., Moser  D.; Prognostic usefulness of positive or negative exercise stress echocardiography for predicting coronary events in ensuing twelve months. Am J Cardiol. 71 1993:646-651.
CrossRef | PubMed
Geleijnse  M.L., Elhendy  A., van Domburg  R.T.; Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. J Am Coll Cardiol. 28 1996:447-454.
CrossRef | PubMed
Smart  S.C., Knickelbine  T., Malik  F., Sagar  K.B.; Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. Circulation. 101 2000:258-263.
CrossRef | PubMed
Hoffmann  R., Lethen  H., Marwick  T.; Analysis of interinstitutional observer agreement in interpretation of dobutamine stress echocardiograms. J Am Coll Cardiol. 27 1996:330-336.
CrossRef | PubMed
Shaw  L.J., Berman  D.S., Maron  D.J.; Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 117 2008:1283-1291.
CrossRef | PubMed
Dall'Armellina  E., Morgan  T.M., Mandapaka  S.; Prediction of cardiac events in patients with reduced left ventricular ejection fraction with dobutamine cardiovascular magnetic resonance assessment of wall motion score index. J Am Coll Cardiol. 52 2008:279-286.
CrossRef | PubMed
Wahl  A., Paetsch  I., Gollesch  A.; Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J. 25 2004:1230-1236.
CrossRef | PubMed
Poldermans  D., Fioretti  P.M., Boersma  E.; Long-term prognostic value of dobutamine-atropine stress echocardiography in 1737 patients with known or suspected coronary artery disease: a single-center experience. Circulation. 99 1999:757-762.
CrossRef | PubMed
Geleijnse  M.L., Fioretti  P.M., Roelandt  J.R.; Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol. 30 1997:595-606.
CrossRef | PubMed
Bjork Ingul  C., Rozis  E., Slordahl  S.A., Marwick  T.H.; Incremental value of strain rate imaging to wall motion analysis for prediction of outcome in patients undergoing dobutamine stress echocardiography. Circulation. 115 2007:1252-1259.
PubMed
Korosoglou  G., Lehrke  S., Wochele  A.; Strain-encoded CMR for the detection of inducible ischemia during intermediate stress. J Am Coll Cardiol Img. 3 2010:361-371.
Verdecchia  P., Schillaci  G., Borgioni  C.; Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 25 1995:871-878.
CrossRef | PubMed
Devereux  R.B., Wachtell  K., Gerdts  E.; Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 292 2004:2350-2356.
CrossRef | PubMed
Kwong  R.Y., Chan  A.K., Brown  K.A.; Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 113 2006:2733-2743.
CrossRef | PubMed
Steel  K., Broderick  R., Gandla  V.; Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation. 120 2009:1390-1400.
CrossRef | PubMed

Correspondence

Latest JACC CME

Continuing Medical Education through JACC is a convenient way to fulfill your CME requirements while learning important information about the latest advances in cardiovascular medicine.

April 2013- JACC CME Activity
Repeat Revascularization and Outcome

March 2013- JACC CME Activity
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction

Feb 2013- JACC CME Activity
Results from the BARI 2D Trial

Jan 2013- JACC CME Activity
Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

Dec 2012- JACC CME Activity
Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

Nov 2012- JACC CME Activity
A Collaborative Analysis of Individual Patient Data From 10 Randomized Trials

Oct 2012- JACC CME Activity
Radiofrequency Ablation of Premature Ventricular Ectopy Improves the Efficacy of Cardiac Resynchronization Therapy in Nonresponders

Sept 2012- JACC CME Activity
Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease

Aug 2012- JACC CME Activity
Reduction in Life-Threatening Ventricular Tachyarrhythmias in Statin-Treated Patients With Nonischemic Cardiomyopathy Enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)

July 2012- JACC CME Activity
Relationship of Beta-Blocker Dose With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction

For previous CME quizzes, please follow this link to CardioSource Lifelong Learning and MOC.

 

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles